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ABSTRACT The P210bcr/abl protein is produced in cells
from patients with Philadelphia chromosome-positive chronic
myelogenous leukemia (CML). Retroviral transfer of the gene
encoding P210bcr/abl into murine bone marrow induces a
granulocytic leukemia that models the chronic phase ofhuman
CML. We have transferred the leukemic clone to syngeneic
animals, albeit with surprising inefficiency, and have observed
CML and clonally related acute leukemias of lymphoid or
myeloid phenotype in some transplant recipients. These data
show that murine CML can result from retroviral transfer of
the bcr/abl gene into pluripotent hematopoietic stem cells, that
infected clones repopulate poorly after adoptive transfer, and
that these clones can give rise to acute leukemia, reflecting
evolution to a phase resembling blast crisis in the human
disease.
In the initial, chronic phase of the human myeloproliferative
disease chronic myelogenous leukemia (CML), the leukemic
myeloid progenitors continue to differentiate into mature
granulocytes (1). This feature distinguishes the chronic phase
of CML from acute myeloid or lymphoid leukemia, which
typically involves the accumulation of primitive hematopoi-
etic cells arrested at an early stage ofdifferentiation. Chronic-
phase CML is unstable, and the disease ultimately progresses
to a terminal stage called blast crisis, which resembles an
acute leukemia.
The Philadelphia chromosome (Ph1) is the cytogenetic
hallmark ofCML (2). It can be detected in all hematopoietic
lineages and is evident in leukemic cells of both chronic and
acute phase, implying that the reciprocal translocation that
gives rise to the Ph' occurs in a stem cell (3, 4). The
translocation leads to an aberrant juxtaposition of chromo-
some 22 bcr sequences with c-abl sequences from chromo-
some 9 (5) and expression ofa 210-kDa bcr/abl fusion protein
(P2i0bcr/abl) (6). P210bcr/abl can transform a variety of hema-
topoietic cell types in vitro (7-11) and in animal model
systems (12-15). However, only retroviral transfer of the
P210bcr/abl gene into murine bone marrow induces a granu-
locytic leukemia that closely resembles the chronic phase of
human CML (13, 15). Mice with the CML-like granulocytic
leukemia succumb to their disease, probably from over-
whelming granulocytosis, and our limited attempts to control
the tumor load with cytotoxic chemotherapy have not been
able to prolong survival (unpublished data). Thus, we have
been unable to observe whether the CML-like granulocytic
leukemia in primary diseased mice resembles human CML in
its tendency to progress to acute leukemia.
To further study the leukemic clone, we have transplanted
bone marrow from primary animals with CML into irradiated
syngeneic recipients. A small number ofsecondary recipients
have developed either CML or acute leukemias of lymphoid
or myeloid phenotype. By analysis of the site of proviral
integration, we demonstrate that the leukemic cells in the
secondary animals derive from the clone that gave rise to
CML in the primary animal. In one case, the clone marked by
the bcr/abl provirus produced myeloid and lymphoid disease
in separate secondary animals, thus verifying that the target
of the initial retroviral infection was a pluripotent hemato-
poietic stem cell. These experiments establish that bcr/abl
induces a CML-like syndrome in mice that recapitulates the
distinctive biological features of both the chronic and acute
phases of the human disease.
MATERUILS AND METHODS
Animals. Primary animals with murine CML were gener-
ated as described (13). Bone marrow for initial retroviral
infection was derived from female mice, and all transplant
recipients were male BALB/c mice between 6 and 12 weeks
of age. The leukemic tissue in DR-1 and FR-1 was shown to
be of female origin by the inability to detect Y chromosome-
specific sequences in tumor samples (unpublished data). For
adoptive transplantation of leukemia, leukemic cells from
various sources were injected intravenously into recipient
mice that had received either 900 cGy of -y-irradiation in two
doses separated by 3 hr (lethal conditioning) or a single dose
of 450 cGy of ^y-irradiation (sublethal conditioning), as de-
scribed in Fig. 1.
Histopathology and Immunohistochemistry. Histological
preparation and staining of tissue specimens from diseased
mice were as described (13). For immunohistochemical stain-
ing of thymus tissue from mouse HR-2, a frozen section of
tissue was incubated with a rat monoclonal antibody against
murine Thy-1.2 (Becton Dickinson) and then with alkaline
phosphatase-conjugated mouse anti-rat IgG (Jackson Immu-
noResearch) and developed with naphthol ASMX phosphate
and fast blue BB (Sigma) to give a dark-blue specific reaction
product (16). The nuclei were counterstained with 0.5%
methyl green.
DNA Hybridization Analysis. DNA (5 jug) from tumor tissue
samples was digested with EcoRI (or with Bgl II, where
indicated), separated by agarose gel electrophoresis, trans-
ferred to nylon membranes, and hybridized with a relevant
probe. The probe for the neomyocin-resistance gene was a
1.2-kilobase Cla I fragment derived from the pGD210 retro-
viral vector, as described (13). The probe for the murine
T-cell-receptor (3-chain locus was a mixture of J,81 and J,82
sequences, supplied by Astar Winoto (University of Califor-
nia, Berkeley, CA). The probe for the murine immunoglob-
ulin A-heavy-chain locus included J1-4 sequences, supplied
by Mark Schlissel (The Johns Hopkins University, Balti-
more).
Abbreviations: CML, chronic myelogenous leukemia; Ph', Philadel-
phia chromosome.
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Fio. 1. Adoptive transplantation ofleukemia. For the transplantation ofbone marrow from DR-1, 3.5 x ilS nucleated marrow cells per mouse
were injected intravenously into five mice that had received sublethal conditioning. For FR-1, 4.5 x 1W nucleated cells per mouse were injected
into three mice that had received lethal conditioning. A mixture of bone marrow and spleen cells was transplanted from HL-2 into recipient
animals; 3 x 106 nucleated cells per mouse were injected into three mice that had received lethal conditioning (K cage) and 1.5 x 10' nucleated
cells per mouse were injected into five mice that had received sublethal conditioning (L cage). For the transplantation oftumor cells from HR-2,
1 x 106 cells from the thymic mass per mouse were injected into five unirradiated recipients. ND, transplantation of mouse IL-1 marrow into
tertiary mice was not done. Disease latency (time after transplant until development of significant morbidity or death) is listed below the
pathologic diagnosis for each animal. T-ALL, acute lymphoid leukemia of T-cell origin; AML, acute myeloid leukemia.
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Fia. 2. Histopathologic and immunologic characterization of the tumor tissue in diseased mice. (A) Spleen from mouse HL-2, stained with
hematoxylin and eosin, demonstrating loss ofnormal follicular architecture and extensive infiltration with granulocytes. (B) Wright-Giemsa stain
ofa cytospin preparation ofbone marrow from mouse IL-1, showing predominance of immature basophils. (C) Thymic mass from mouse HR-2,
stained with hematoxylin and eosin, demonstrating destruction ofthymic architecture and replacement with homogenous mononuclear cell type.
(D) Immunohistochemical stain of thymic mass from mouse HR-2 with Thy-i antisera. The presence of the Thy-1 antigen at the cell surface
is indicated by the deep-blue reaction product.
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FIG. 3. DNA hybridization analysis of tumor tissue. Tumor DNA samples are as listed above each lane. (A) Determination of the site of
proviral integration in tumor tissue. The blot was hybridized with a probe derived from neomyocin-resistance gene sequences. EcoRI generates
a specific fragment for each site ofproviral integration. Identity of the integration site was verified by a second enzyme, Bgi H. (B) Determination
of the rearrangement status of the murine T-cell-receptor P-chain locus. The probe was a mixture of J.81 and J,82 sequences and detects
rearrangements in tumor samples HR-2 and TL-2. (C) Determination of the rearrangement status of the murine immunoglobulin pA-heavy-chain
locus. The probe included J1-4 sequences and verified germ-line status in all samples.
RESULTS
The scheme for transplanting marrow from primary animals
with CML is shown in Fig. 1. Mouse DR-1 was diagnosed
with CML on the basis of hematologic and pathologic criteria
(13). Bone marrow was transplanted into five syngeneic
recipients pretreated with a sublethal dose of irradiation (450
cGy). Recipient mice were monitored by periodic sampling of
peripheral blood and examined for clinical signs of disease
(e.g., splenomegaly, malaise). After several months of ap-
parently normal hematopoiesis, mouse HL-2 became mori-
bund 4.5 months after transplant. At autopsy, this mouse had
an elevated leukocyte count (26,250 cells per mm3) with a
differential increase in granulocytes and immature myeloid
forms and marked splenomegaly (0.54 g). Histopathologic
analysis of the spleen (Fig. 2), liver, and bone marrow
showed extensive accumulations of granulocytes and imma-
ture myeloid cells, consistent with a pathologic diagnosis of
CML. After an initial period of apparently normal he-
matopoiesis, mouse HR-2 developed palpable splenomegaly
and a mild leukocytosis (15,000 leukocytes per mm3, with
50%6 immature cells and 40% granulocytes) 3.5 months after
transplant. Over time, immature blast cells came to predom-
inate in the peripheral blood, and HR-2 was discovered dead
6.5 months after transplant. At autopsy, HR-2 was found to
have a large thymic mass (0.49 g) and leukemic blasts in the
bone marrow. The leukemic cells in this animal stained
positive for the T-cell marker Thy-1 (Fig. 2) and showed
rearrangements at the
.
locus of the T-cell-receptor gene and
germ-line configuration of the immunoglobulin ,u-heavy-
chain gene (Fig. 3). These findings are consistent with a
diagnosis of acute lymphoid leukemia of T-cell origin. The
remaining three mice later died with tumors ofhost-cell origin
that did not carry the bcr/abl retrovirus.
Tumor tissue from the diseased secondary mice (HL-2 and
HR-2) was transplanted into tertiary animals. Fourteen
months after transplant, eight recipients of cells from HL-2
were free of hematologic disease and thus apparently failed
to reconstitute with the leukemic clone. In contrast, each of
five recipients of lymphoblasts from HR-2 rapidly developed
an acute lymphoblastic leukemia similar to that in HR-2.
Thus, the leukemic clones in the secondary animals HL-2 and
HR-2 not only differ in phenotype but also differ upon
transplantation, with that in HR-2 exhibiting markedly en-
hanced transplantability perhaps as a result of additional
genetic alterations.
DNA from the tumor tissue of diseased mice was analyzed
to determine the integration site of the bcr/abl provirus (Fig.
3). Leukemic cells in primary (DR-1), secondary (HL-2 and
HR-2), and tertiary animals (TL-2) have the same retroviral
integration, establishing that they are derived from a single
infected cell. We showed previously that the retrovirally
marked clone in primary mice with CML gives rise to day 14
spleen colonies (splenic colony-forming units) in secondary
transplant recipients (13) and thus represents a multipotential
hematopoietic progenitor cell. By repopulating both myeloid
and lymphoid cell lineages (in HL-2 and HR-2, respectively),
the marked clone in mouse DR-1 has properties of a pluri-
potent hematopoietic stem cell.
Three recipients of bone marrow from another primary
animal with CML (FR-1) (13) had normal peripheral leuko-
cyte counts at 4 weeks, but died 6 weeks after transplant. The
only animal suitable for pathologic examination (mouse IL-1)
was morbidly anemic (hematocrit of5%) and pancytopenic at
autopsy. On examination, the bone marrow was hypercellu-
lar, with a predominant immature basophilic or mast cell type
(Fig. 2). The spleen lacked evidence of follicular structure
and showed extensive replacement with basophils. The pro-
viral integration site in DNA isolated from mouse IL-1 was
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identical to that in FR-1 (Fig. 3). The disease in mouse IL-1
thus represents transformation of the leukemic clone to an
acute basophilic leukemia, which has been reported as a form
of myeloid blast crisis of CML in humans (17).
DISCUSSION
In mice, it appears that a CML-like syndrome can be induced
by infection of a pluripotent hematopoietic stem cell with a
retrovirus carrying the bcr/abl gene of the Ph'. We have
transplanted murine CML into secondary recipients and have
observed transformation of the retrovirally infected clone
from chronic to acute leukemia, a feature reminiscent of
human CML. However, transplantation of murine CML to
secondary recipients is surprisingly inefficient. In addition to
the two animals described here, we have attempted to
transfer disease from two other primary animals without
success. After passage to HL-2, the clone from DR-1 failed
to repopulate tertiary recipients, suggesting that the leukemic
clone was not expanded by serial transplantation. In addition,
the latency of disease in secondary animals is variable and
can be longer than for any primary animal, in which disease
occurs soon after transplant (13). Several months of appar-
ently normal hematopoiesis intervened before leukemias
appeared in HL-2 and HR-2.
The Ph'-positive stem cell in human CML may not have a
proliferative or competitive advantage over normal stem
cells. When grown in long-term bone marrow culture, the
Ph'-positive clone is selectively lost in many cases and is
overgrown by normal clones (18). In a few cases, chronic-
phase CML patients treated with intensive chemotherapy
alone or in combination with autologous marrow transplan-
tation have achieved cytogenetic remission for significant
periods (19, 20). These data demonstrate that normal stem
cells exist in the bone marrow of CML patients. The accu-
mulation of cells in human CML patients apparently occurs
in more differentiated compartments (21), leading to large
numbers of Ph'-positive committed progenitor cells in the
marrow. The proliferative or competitive advantage of the
Ph'-positive clone may not be manifest within the stem cell
compartment itself.
In the mouse model system, the bcr/abl-infected stem cell
may represent only a minority of stem cells, making trans-
plantation inefficient. Marrow transplantation may reset or
"reshuffle" the stem cell compartment, enabling normal
clones to repopulate secondary animals. Early after bone
marrow transplantation in mice, only a limited number of
stem cells contribute to peripheral blood formation, while the
rest presumably remain quiescent (22, 23). CML occurs early
after the transfer of infected marrow into primary animals
because the bcr/abl retrovirus infects cycling stem cells;
however, disease latency in secondary animals is unpredict-
able. Secondary animals may not develop disease until an
infected stem cell is recruited into cycle and only then would
the p210bcr/abl protein exhibit its leukemogenic function,
perhaps in a myeloid progenitor that proliferates in response
to bcr/abl. Fractionation protocols that enrich for stem cells
(23-25) and treatments that recruit stem cells into cycle (e.g.,
5-fluorouracil) may allow for an increased efficiency of
disease transfer.
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